FDA Haryana booked Blood Centre for selling Plasma more than the price fixed, FIR lodged

Hence to sale a blood component in violation above rate prescribed by competent authority is also a matter of cheating and dishonesty and this case is clear cut case of profiteering.

833
Blood
Picture: Pixabay

Last Updated on May 22, 2022 by The Health Master

Food and Drugs Administration (FDA) Haryana raided Blood Centre and caught them red handed selling plasma Plasma more than the price fixed. FIR has also been lodged against the Blood Centre and the purchasers of the plasma.

FDA Haryana
FDA Haryana

On 21-05-2022 the team comprising of Sarika Malik, Senior Drugs Control officer, Kurukshetra Zone, Kurukshetra, Amandeep Singh Chauhan, Drugs Control officer Nuh, Gurugram Zone, Sandeep Kumar, Drugs Inspector, CDSCO, NZ Ghaziabad Under supervision of Ripan Mehta, Asst. State Drugs Controller, FDA Haryana visited Shah Krishan Sewa Blood Centre, Near Koel Complex, Kaithal, Haryana

The blood centre found indulged in business of profiteering through the way of selling Fresh Frozen Plasma BP to Virchow Biotech Private Limited and Intas Pharmaceuticals Limited for Rs. 2800/- and Rs. 2700/- per litre violating the Plasma Policy of, Haryana State Blood Transfusion Council, where the price of Plasma had been fixed Rs. 1600/- per litre.

Blood Products and Plasma substitutes is in National List of Essential Medicine issued by National Pharmaceutical Pricing Agency (NPPA) an agency who fixes the MRP of the Medicines. In the present case NPPA is not the fixing agency for Plasma and the State Blood Transfusion Council are price fixing agency for Plasma.

The MoU of Intas Pharmaceuticals Limited mentions rate of FFP as Rs. 2700/- however the component FFP sold for Rs. 2900/-, further in the agreement with Virchow Biotech Private Limited there was no rate specified in the agreement, however the component FFP was sold for Rs. 2800/- per litre.

None of the MoU of Virchow Biotech Private Limited and Intas Pharmaceuticals Limited with the blood center was sent to the State Drugs Controller for approval before supplying excess plasma to indigenous fractionators violating the Plasma Policy.

Hence to sale a blood component in violation above rate prescribed by competent authority is also a matter of cheating and dishonesty and this case is clear cut case of profiteering.

Further, selling component i.e. Fresh Frozen Plasma BP at higher prices which is essentially required by masses and fractionators to prevent the deadly disease the person named above have done a serious offence under Drugs Price Control Order 2013 (DPCO) and order under Section 3 of Essential Commodities 1955 Act punishable under Section 7 of the EC Act in violation of selling above prescribed rates.

FDA Haryana lodged a FIR against representatives / responsible persons of Shah Krishan Sewa Blood Centre, Virchow Biotech Private Limited and Intas Pharmaceuticals Limited and all other person responsible for violation of law of land i.e. Indian Penal Code and Drugs Price Control Order 2013 and Essential Commodities Act 1955 for overcharging and also for the act of cheating and dishonesty of all for financial gains by selling the blood components i.e. Fresh Frozen Plasma BP.

Latest on National Pharmaceutical Pricing Authority (NPPA)

Latest notifications – DPCO / NPPA

Latest Notifications: EC Act (Essential Commodities Act)

FAQs – On DPCO: Drugs (Prices Control) Order, 2013

Procedure to obtain license for Blood Centre (Blood Bank)

Latest Notifications: Blood Centre / Bank

Blood Centre (Bank) – requirements at a glance

FAQs – on Blood Bank / Centre (Part-1)

FAQs – on Blood Bank / Centre (Part-2)

FAQs – on Blood Bank / Centre (Part-3)

FAQs – on Blood Bags and its Testing

Blood Storage Centre

Mandatory requirements for Blood donation camps

FAQs on Legal Metrology & Blood Bags

Bombay Blood Group

Pharmacopoeial status of Blood and its components

Your Guide to Preventing and Treating Blood Clots

Adequate and safe blood transfusion for all: Article

Why India needs more blood donors: Article

FDA lodged FIR for manufacturing BP monitoring machines without license

USFDA gives nod to Glenmark for Abiraterone Acetate tablets USP 500 mg

Govt amends Rules to add suspension and cancellation of license provisions…

CDSCO approves Boehringer Ingelheim’s Jardiance for treating heart failure

USFDA completes inspection of Aurobindo Pharma with no remaining deficiencies

Regulatory framework for Nutraceutical

Govt preparing roadmap for strengthening testing infrastructure for Medical Devices

Govt: Conduct due diligence on claims of local manufacturers of 67 Drugs

USFDA-Gujarat FDCA Regulatory Forum to be held from 17th to 19th May

FAQs – on Schedule-P (Expiry Date of drugs)

Latest Notifications regarding Pharmaceuticals

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner